6th Jun 2005 06:00
6 June 2005Shire Pharmaceuticals Group plc (the "Company")Application has been made to the UK Listing Authority and the London StockExchange for a listing of 60,000 ordinary shares of 5p each in the Company tobe admitted to the Official List.These shares, ranking pari passu in all respects with the existing shares inissue, have been issued pursuant to the exchange of certain Exchangeable Sharesin Shire Acquisition Inc., in accordance with the terms of the Merger Agreementwith BioChem Pharma Inc.T MayCompany SecretaryFor further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing projects and marketing products in theareas of central nervous system (CNS), gastrointestinal (GI), and renaldiseases. Shire has operations in the world's key pharmaceutical markets (US,Canada, UK, France, Italy, Spain and Germany) as well as a specialist drugdelivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com.Page 2 of 1Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire